Pfizer Inc.

NYSE:PFE Stock Report

Market Cap: US$142.2b

Pfizer Valuation

Is PFE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PFE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PFE ($24.94) is trading below our estimate of fair value ($78.91)

Significantly Below Fair Value: PFE is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PFE?

Key metric: As PFE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PFE. This is calculated by dividing PFE's market cap by their current earnings.
What is PFE's PE Ratio?
PE Ratio33.1x
EarningsUS$4.27b
Market CapUS$142.24b

Price to Earnings Ratio vs Peers

How does PFE's PE Ratio compare to its peers?

The above table shows the PE ratio for PFE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average39.7x
MRK Merck
20.3x15.6%US$244.2b
ZTS Zoetis
32.6x9.9%US$79.2b
JNJ Johnson & Johnson
25x10.6%US$368.4b
LLY Eli Lilly
81.1x29.5%US$657.1b
PFE Pfizer
33.1x16.8%US$142.2b

Price-To-Earnings vs Peers: PFE is good value based on its Price-To-Earnings Ratio (33.1x) compared to the peer average (39.7x).

Price to Earnings Ratio vs Industry

How does PFE's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
2.9x-7.1%US$3.76b
NDOI Endo
0.6xn/aUS$1.91b
PROC Procaps Group
1.2xn/aUS$59.68m
KPRX Kiora Pharmaceuticals
1.8x-40.4%US$9.59m
PFE 33.1xIndustry Avg. 20.1xNo. of Companies12PE01224364860+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PFE is expensive based on its Price-To-Earnings Ratio (33.1x) compared to the US Pharmaceuticals industry average (20.1x).

Price to Earnings Ratio vs Fair Ratio

What is PFE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PFE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.1x
Fair PE Ratio36.8x

Price-To-Earnings vs Fair Ratio: PFE is good value based on its Price-To-Earnings Ratio (33.1x) compared to the estimated Fair Price-To-Earnings Ratio (36.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PFE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$24.94
US$32.55
+30.5%
13.9%US$45.00US$25.00n/a24
Nov ’25US$28.09
US$33.41
+18.9%
13.1%US$45.00US$27.00n/a23
Oct ’25US$28.67
US$33.56
+17.1%
13.4%US$45.00US$27.00n/a22
Sep ’25US$29.01
US$33.23
+14.6%
13.0%US$45.00US$27.00n/a22
Aug ’25US$30.65
US$32.87
+7.2%
13.8%US$45.00US$27.00n/a22
Jul ’25US$28.22
US$31.92
+13.1%
15.1%US$45.00US$27.00n/a22
Jun ’25US$28.66
US$31.92
+11.4%
15.1%US$45.00US$27.00n/a22
May ’25US$27.18
US$31.62
+16.3%
15.4%US$45.00US$26.00n/a22
Apr ’25US$27.72
US$32.70
+18.0%
18.6%US$50.00US$26.00n/a22
Mar ’25US$26.59
US$32.71
+23.0%
18.4%US$50.00US$26.00n/a23
Feb ’25US$27.29
US$33.00
+20.9%
19.3%US$50.00US$26.00n/a22
Jan ’25US$28.79
US$33.05
+14.8%
19.9%US$50.00US$23.00n/a22
Dec ’24US$28.91
US$40.41
+39.8%
23.1%US$75.00US$32.00n/a22
Nov ’24US$30.51
US$40.91
+34.1%
22.4%US$75.00US$32.00US$28.0922
Oct ’24US$33.17
US$44.41
+33.9%
21.3%US$75.00US$32.00US$28.6722
Sep ’24US$35.78
US$44.27
+23.7%
21.0%US$75.00US$32.00US$29.0123
Aug ’24US$35.61
US$45.69
+28.3%
19.9%US$75.00US$35.00US$30.6523
Jul ’24US$36.68
US$46.31
+26.3%
19.2%US$75.00US$35.00US$28.2222
Jun ’24US$38.02
US$46.68
+22.8%
18.8%US$75.00US$35.00US$28.6622
May ’24US$39.21
US$49.09
+25.2%
16.1%US$75.00US$40.00US$27.1822
Apr ’24US$40.80
US$50.50
+23.8%
16.0%US$75.00US$40.00US$27.7222
Mar ’24US$40.18
US$51.35
+27.8%
15.3%US$75.00US$40.00US$26.5921
Feb ’24US$43.97
US$51.59
+17.3%
15.1%US$75.00US$40.00US$27.2921
Jan ’24US$51.24
US$54.49
+6.3%
12.3%US$75.00US$44.00US$28.7921
Dec ’23US$51.08
US$53.78
+5.3%
12.6%US$75.00US$44.00US$28.9121
Nov ’23US$48.01
US$53.65
+11.7%
13.7%US$75.00US$44.00US$30.5119

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%